U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06860282) titled 'A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects' on Feb. 24.
Brief Summary: This study is divided into two parts, including Part I: a randomized, open-label, positive drug-controlled, single ascending dose (SAD) study, a food effect (FE) study, and Part II: a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study.
Study Start Date: Dec. 26, 2022
Study Type: INTERVENTIONAL
Condition:
COVID-19
Coronavirus Pneumonia
Intervention:
DRUG: Remdesivir
Intravenous remdesivir 100 mg
DRUG: CX2101A
CX2101A enteric-coated tablet
DRUG: Placebo
CX2101A placebo enteric-coated tablet...